Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Pond, Gregory
  • Armstrong, AJ
  • Wood, BA
  • Brookes, M
  • Leopold, LH
  • Berry, WR
  • De Wit, R
  • Eisenberger, MA
  • Tannock, I
  • Sonpavde, G

publication date

  • May 20, 2011